Condition: Acute Myeloid Leukemia (AML) · Sponsor: Kyowa Kirin Co., Ltd.
This is the first study to administer ziftomenib to Japanese patients. In this study, the efficacy, safety, and pharmacokinetics of ziftomenib will be evaluated in patients with relapsed or refractory NPM1-mutated acute myeloid leukemia
This description comes directly from the study's public registry record.
Kyowa Kirin, Inc. · 1-609-919-1100 · kkd.clintrial.82@kyowakirin.com
Kyowa Kirin Co., Ltd. · clinical.info.jp@kyowakirin.com
Always discuss trial participation with your own doctor first.
| Chiba Aoba Municipal Hospital | Chiba, Japan | Recruiting |
| Gifu Municipal Hospital | Gifu, Japan | Recruiting |
| Hyogo Medical University Hospital | Hyōgo, Japan | Not Yet Recruiting |
| Mito Medical Center | Ibaraki, Japan | Recruiting |
| Imamura General Hospital | Kagoshima, Japan | Recruiting |
| Kanagawa Cancer Center | Kanagawa, Japan | Recruiting |
| Kyoto University Hospital | Kyoto, Japan | Not Yet Recruiting |
| Tohoku University Hospital | Miyagi, Japan | Recruiting |
| Matsumoto National Hospital | Nagano, Japan | Recruiting |
| Nagasaki University Hospital | Nagasaki, Japan | Recruiting |
| Kurashiki Central Hospital | Okayama, Japan | Recruiting |
| Okayama University Hospital | Okayama, Japan | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07623616